BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016;64:292-300. [PMID: 26453968 DOI: 10.1016/j.jhep.2015.09.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. J Viral Hepat 2018;25:1515-25. [PMID: 30141252 DOI: 10.1111/jvh.12986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Castedal M, Segenmark M, Cederberg S, Skoglund C, Weiland O. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience. Scand J Gastroenterol 2017;52:585-8. [PMID: 28270038 DOI: 10.1080/00365521.2017.1283439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
3 Montanaro N, Melis M, Proni S, Chiabrando G, Motola D. Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations. Eur J Clin Pharmacol 2017;73:479-85. [PMID: 28035436 DOI: 10.1007/s00228-016-2186-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Li Z, Liu Y, Zhang Y, Shao X, Luo Q, Guo X, Lin G, Cai Q, Zhao Z, Chong Y. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. Biomed Res Int 2017;2017:9849823. [PMID: 29164151 DOI: 10.1155/2017/9849823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Takehara T, Chayama K, Kurosaki M, Yatsuhashi H, Tanaka Y, Hiramatsu N, Sakamoto N, Asahina Y, Nozaki A, Nakano T, Hagiwara Y, Shimizu H, Yoshida H, Huang Y, Biermer M, Vijgen L, Hayashi N. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol 2020;55:640-52. [DOI: 10.1007/s00535-020-01672-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ferreira VL, Assis Jarek NA, Tonin FS, Borba HH, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016;41:478-85. [PMID: 27440554 DOI: 10.1111/jcpt.12426] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
7 Sherman KE, Ke R, Rouster SD, Abdel-Hameed EA, Park C, Palascak J, Perelson AS. Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs. Haemophilia 2016;22:543-8. [PMID: 26936587 DOI: 10.1111/hae.12918] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
9 Zhang H, Zhu X, Li Q, Lou J, Sun J, Shen Z, Chen H, Li X, Wu M, Li C, Liu J, Liu C, Hu Y, Wang J, Chen G, Ding Y, Niu J. Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus. J Pharm Pharmacol 2018;70:855-64. [PMID: 29630721 DOI: 10.1111/jphp.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ku KS, Chodavarapu RK, Martin R, Miller MD, Mo H, Svarovskaia ES. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol 2016;54:1835-41. [PMID: 27147726 DOI: 10.1128/JCM.00238-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Doncheva NT, Domingues FS, McGivern DR, Shimakami T, Zeuzem S, Lengauer T, Lange CM, Albrecht M, Welsch C. Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants. J Mol Biol 2019;431:2354-68. [PMID: 31051172 DOI: 10.1016/j.jmb.2019.04.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Pomeroy JJ, Drusano GL, Rodriquez JL, Brown AN. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system. Antiviral Res 2017;146:149-52. [PMID: 28882564 DOI: 10.1016/j.antiviral.2017.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Gussler JW, Campo DS, Dimitrova Z, Skums P, Khudyakov Y. Primary case inference in viral outbreaks through analysis of intra-host variant population. BMC Bioinformatics 2022;23:62. [PMID: 35135469 DOI: 10.1186/s12859-022-04585-2] [Reference Citation Analysis]
14 Klimova EA, Burnevich EZ, Chulanov VP, Gusev DA, Znoyko OO, Batskikh SN, Kizlo SN, Mamonova NA, Tarkhova EP, Krasavina EN, Samsonov MY, Yushchuk ND. [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C]. Ter Arkh 2019;91:67-74. [PMID: 32598756 DOI: 10.26442/00403660.2019.08.000384] [Reference Citation Analysis]
15 Jiménez-Macías FM, Cabanillas-Casafranca M, Maraver-Zamora M, Romero-Herrera G, García-García F, Correia-Varela-Almeida A, Cabello-Fernández A, Ramos-Lora M. Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C. Med Clin (Barc) 2017;149:375-82. [PMID: 28416232 DOI: 10.1016/j.medcli.2017.03.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Vivancos M, Moreno A, Quereda C. Tratamiento del virus de la hepatitis C con antivirales de acción directa: Aspectos prácticos y situación actual. Revista Clínica Española 2018;218:29-37. [DOI: 10.1016/j.rce.2017.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Yang X, Zhou Y. Improve efficiency and reduce bias of Cox regression models for two-stage randomization designs using auxiliary covariates: IMPROVE EFFICIENCY AND REDUCE BIAS OF COX REGRESSION MODELS FOR TSRDS. Statist Med 2017;36:1683-95. [DOI: 10.1002/sim.7252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, Han Q, Lv Y, Liu Z. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. Int J Antimicrob Agents 2019;54:780-9. [PMID: 31284039 DOI: 10.1016/j.ijantimicag.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver Int 2017;37:1304-13. [PMID: 28135777 DOI: 10.1111/liv.13376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. J Viral Hepat 2017;24:442-53. [DOI: 10.1111/jvh.12681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
21 Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat 2017;24:287-94. [PMID: 27878906 DOI: 10.1111/jvh.12645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
22 Forns X, Berenguer M, Herzer K, Sterneck M, Donato MF, Andreone P, Fagiuoli S, Cieciura T, Durlik M, Calleja JL, Mariño Z, Shukla U, Verbinnen T, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, Janssen K, Kalmeijer R, Jessner W. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. Transpl Infect Dis 2017;19. [PMID: 28295849 DOI: 10.1111/tid.12696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
23 Youssef AF, Issa YM, Nabil KM. Development and Validation of a New Method for the Determination of Anti-hepatitis C Agent Simeprevir in Human Plasma using HPLC with Fluorescence Detection. CAC 2020;16:428-35. [DOI: 10.2174/1573411015666181217121619] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
25 McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents. Antimicrob Agents Chemother 2019;63:e02205-18. [PMID: 30718256 DOI: 10.1128/AAC.02205-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Raja R, Baral S, Dixit NM. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era. Immunol Rev 2018;285:55-71. [PMID: 30129199 DOI: 10.1111/imr.12689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Sci Rep 2019;9:585. [PMID: 30679515 DOI: 10.1038/s41598-018-36734-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J 2017;14:88. [PMID: 28464951 DOI: 10.1186/s12985-017-0753-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
29 Stenfors BA, Staples RJ, Biros SM, Ngassa FN. Crystal structure of N,N-diisopropyl-4-methyl-benzene-sulfonamide. Acta Crystallogr E Crystallogr Commun 2020;76:1018-21. [PMID: 32695444 DOI: 10.1107/S2056989020007185] [Reference Citation Analysis]
30 MacBrayne CE, Kiser JJ. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV. Clin Infect Dis 2016;63 Suppl 1:S12-23. [PMID: 27363437 DOI: 10.1093/cid/ciw220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
31 Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. Clin Drug Investig 2017;37:635-46. [PMID: 28409482 DOI: 10.1007/s40261-017-0521-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]